Oleg Gluz, MD; Ulrike A. Nitz, MD; Matthias Christgen, MD, PhD; et al.
This randomized clinical trial aims to determine whether neoadjuvant de-escalated chemotherapy is superior to endocrine therapy, both in combination with pertuzumab and trastuzumab, in a highly heterogeneous hormone receptor–positive/ERBB2-positive early breast cancer.